OTCMKTS:MRNA - Marina Biotech Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$20.11 -0.24 (-1.18 %)
(As of 03/20/2019 11:26 AM ET)
Previous Close$20.35
Today's Range$20.00 - $20.76
52-Week Range$13.03 - $24.40
Volume115,600 shs
Average Volume1.04 million shs
Market Capitalization$6.62 billion
P/E RatioN/A
Dividend YieldN/A
Marina Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension. Its clinical development programs include IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. The company is headquartered in City of Industry, California.

Receive MRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:MRNA
Previous SymbolOTCMKTS:MRNAD



Sales & Book Value

Annual SalesN/A



Market Cap$6.62 billion
Next Earnings DateN/A
OptionableNot Optionable

Marina Biotech (OTCMKTS:MRNA) Frequently Asked Questions

What is Marina Biotech's stock symbol?

Marina Biotech trades on the OTCMKTS under the ticker symbol "MRNA."

How were Marina Biotech's earnings last quarter?

Marina Biotech, Inc. (OTCMKTS:MRNA) posted its quarterly earnings results on Friday, May, 18th. The biotechnology company reported ($0.13) EPS for the quarter. View Marina Biotech's Earnings History.

What price target have analysts set for MRNA?

8 brokerages have issued 1 year price objectives for Marina Biotech's stock. Their forecasts range from $20.00 to $29.00. On average, they anticipate Marina Biotech's share price to reach $24.3750 in the next year. This suggests a possible upside of 21.2% from the stock's current price. View Analyst Price Targets for Marina Biotech.

What is the consensus analysts' recommendation for Marina Biotech?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marina Biotech in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marina Biotech.

Has Marina Biotech been receiving favorable news coverage?

Media headlines about MRNA stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Marina Biotech earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.

Are investors shorting Marina Biotech?

Marina Biotech saw a increase in short interest in the month of February. As of February 15th, there was short interest totalling 11,443,101 shares, an increase of 22.4% from the January 31st total of 9,349,410 shares. Based on an average daily trading volume, of 878,141 shares, the days-to-cover ratio is presently 13.0 days. Approximately 6.0% of the shares of the stock are short sold. View Marina Biotech's Current Options Chain.

Who are some of Marina Biotech's key competitors?

What other stocks do shareholders of Marina Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marina Biotech investors own include NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Micron Technology (MU), CVS Health (CVS), Activision Blizzard (ATVI), Square (SQ), Constellation Brands (STZ), Netflix (NFLX) and JD.Com (JD).

Who are Marina Biotech's key executives?

Marina Biotech's management team includes the folowing people:
  • Mr. Erik Emerson, Chief Commercial Officer & Director (Age 47)
  • Mr. Robert C. Moscato Jr., CEO & Director (Age 42)
  • Mr. Amit Shah, Chief Financial Officer (Age 52)
  • Mr. Mihir Munsif, Chief Operating Officer (Age 55)
  • Dr. Larn Hwang, Chief Scientific Officer (Age 55)

When does Marina Biotech's lock-up period expire?

Marina Biotech's lock-up period expires on Wednesday, June 5th. Marina Biotech had issued 26,275,993 shares in its public offering on December 7th. The total size of the offering was $604,347,839 based on an initial share price of $23.00. After the expiration of Marina Biotech's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Who are Marina Biotech's major shareholders?

Marina Biotech's stock is owned by a number of of institutional and retail investors. Top institutional investors include Canada Pension Plan Investment Board (0.49%), Essex Investment Management Co. LLC (0.00%) and Essex Investment Management Co. LLC (0.00%). Company insiders that own Marina Biotech stock include Joseph W Ramelli and Vuong Trieu. View Institutional Ownership Trends for Marina Biotech.

Which institutional investors are buying Marina Biotech stock?

MRNA stock was bought by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Essex Investment Management Co. LLC and Essex Investment Management Co. LLC. Company insiders that have bought Marina Biotech stock in the last two years include Joseph W Ramelli and Vuong Trieu. View Insider Buying and Selling for Marina Biotech.

How do I buy shares of Marina Biotech?

Shares of MRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Marina Biotech's stock price today?

One share of MRNA stock can currently be purchased for approximately $20.11.

How big of a company is Marina Biotech?

Marina Biotech has a market capitalization of $6.62 billion.

What is Marina Biotech's official website?

The official website for Marina Biotech is http://www.marinabio.com.

How can I contact Marina Biotech?

Marina Biotech's mailing address is 17870 CASTLETON STREET SUITE 250, CITY OF INDUSTRY CA, 91748. The biotechnology company can be reached via phone at 626-964-5788 or via email at [email protected]

MarketBeat Community Rating for Marina Biotech (OTCMKTS MRNA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  178
MarketBeat's community ratings are surveys of what our community members think about Marina Biotech and other stocks. Vote "Outperform" if you believe MRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel